BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 18844975)

  • 1. Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease.
    van Roon-Mom WM; Pepers BA; 't Hoen PA; Verwijmeren CA; den Dunnen JT; Dorsman JC; van Ommen GB
    BMC Mol Biol; 2008 Oct; 9():84. PubMed ID: 18844975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat.
    Clemens LE; Weber JJ; Wlodkowski TT; Yu-Taeger L; Michaud M; Calaminus C; Eckert SH; Gaca J; Weiss A; Magg JC; Jansson EK; Eckert GP; Pichler BJ; Bordet T; Pruss RM; Riess O; Nguyen HP
    Brain; 2015 Dec; 138(Pt 12):3632-53. PubMed ID: 26490331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology.
    Yohrling GJ; Jiang GC; DeJohn MM; Miller DW; Young AB; Vrana KE; Cha JH
    Brain Res Mol Brain Res; 2003 Nov; 119(1):28-36. PubMed ID: 14597227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
    Cyr M; Sotnikova TD; Gainetdinov RR; Caron MG
    FASEB J; 2006 Dec; 20(14):2541-3. PubMed ID: 17065224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition of autophagy flux.
    Lee H; Noh JY; Oh Y; Kim Y; Chang JW; Chung CW; Lee ST; Kim M; Ryu H; Jung YK
    Hum Mol Genet; 2012 Jan; 21(1):101-14. PubMed ID: 21954231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model.
    Nguyen T; Hamby A; Massa SM
    Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11840-5. PubMed ID: 16087879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.
    Charvin D; Vanhoutte P; Pagès C; Borrelli E; Caboche J
    Proc Natl Acad Sci U S A; 2005 Aug; 102(34):12218-23. PubMed ID: 16103364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micro RNA-214 contributes to proteasome independent downregulation of beta catenin in Huntington's disease knock-in striatal cell model STHdhQ111/Q111.
    Ghatak S; Raha S
    Biochem Biophys Res Commun; 2015 Apr; 459(3):509-14. PubMed ID: 25747711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.
    van Hagen M; Piebes DGE; de Leeuw WC; Vuist IM; van Roon-Mom WMC; Moerland PD; Verschure PJ
    BMC Genomics; 2017 May; 18(1):373. PubMed ID: 28499347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 mice.
    Young D; Mayer F; Vidotto N; Schweizer T; Berth R; Abramowski D; Shimshek DR; van der Putten PH; Schmid P
    PLoS One; 2013; 8(9):e75108. PubMed ID: 24086450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
    Dunah AW; Jeong H; Griffin A; Kim YM; Standaert DG; Hersch SM; Mouradian MM; Young AB; Tanese N; Krainc D
    Science; 2002 Jun; 296(5576):2238-43. PubMed ID: 11988536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained effects of nonallele-specific Huntingtin silencing.
    Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
    Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of neurodegeneration in Huntington's disease.
    Gil JM; Rego AC
    Eur J Neurosci; 2008 Jun; 27(11):2803-20. PubMed ID: 18588526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short G-rich oligonucleotides as a potential therapeutic for Huntington's Disease.
    Skogen M; Roth J; Yerkes S; Parekh-Olmedo H; Kmiec E
    BMC Neurosci; 2006 Oct; 7():65. PubMed ID: 17014717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huntingtin aggregation kinetics and their pathological role in a Drosophila Huntington's disease model.
    Weiss KR; Kimura Y; Lee WC; Littleton JT
    Genetics; 2012 Feb; 190(2):581-600. PubMed ID: 22095086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
    Wyttenbach A; Swartz J; Kita H; Thykjaer T; Carmichael J; Bradley J; Brown R; Maxwell M; Schapira A; Orntoft TF; Kato K; Rubinsztein DC
    Hum Mol Genet; 2001 Aug; 10(17):1829-45. PubMed ID: 11532992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Adeno Associated Viral (AAV) vector type 9 delivery of Ex1-Q138-mutant huntingtin in the rat striatum as a short-time model for in vivo studies in drug discovery.
    Ceccarelli I; Fiengo P; Remelli R; Miragliotta V; Rossini L; Biotti I; Cappelli A; Petricca L; La Rosa S; Caricasole A; Pollio G; Scali C
    Neurobiol Dis; 2016 Feb; 86():41-51. PubMed ID: 26626080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
    de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
    J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.
    Weiss A; Klein C; Woodman B; Sathasivam K; Bibel M; Régulier E; Bates GP; Paganetti P
    J Neurochem; 2008 Feb; 104(3):846-58. PubMed ID: 17986219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.